Headache Clinical Trials
CHRONIC MIGRAINE
I5Q-MC-CGAT: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent
Patients 12 to 17 Years of Age with Chronic Migraine
Sponsor: Eli Lilly Pharmaceuticals
Phase of Development: Phase III
Study Duration: 18 Months
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
CLIN-52120-463: A Phase III, Randomised, Double-Blind, Placebo-controlled, Multicentre, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants
Sponsor: Ipsen Innovation
Phase of Development: Phase III
Study Duration: Up to 60 weeks
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
STCM02: A Pivotal Study Evaluating Safety and Efficacy of the ShiraTronics Migraine Therapy System in Relieving, Interrupting, and Preventing Chronic Migraine (RELIEV-CM2)
Sponsor: ShiraTronics
Phase of Development: Pivotal Study
Study Duration: Approximately 14 months
Enrollment Status: Open
Sub-Investigator: Rajiv Aggarwal, M.D.
Principal Investigator: Rano Faltas, M.D. – iSpine Clinics
EPISODIC MIGRAINE
3110-305-002: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)
Sponsor: Abbvie
Phase of Development: III
Study duration: 1-6 months
Enrollment: Open
Principal Investigator: Rajiv Aggarwal, M.D.
3110-306-002: A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)
Sponsor: Abbvie
Phase of Development: III
Study duration: 12 months
Enrollment: Open
Principal Investigator: Rajiv Aggarwal, M.D.
H8H-MC-LAHV: Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine
Sponsor: Eli Lilly Pharmaceuticals
Phase of Development: Phase III
Study Duration: Up to 12 weeks
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
H8H-MC-LAHW: A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine
Sponsor: Eli Lilly Pharmaceuticals
Phase of Development: Phase III
Study Duration: 52 weeks
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
I5Q-MC-CGAS: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine
Sponsor: Eli Lilly Pharmaceuticals
Phase of Development: Phase III
Study Duration: 18 Months
Enrollment Status: Open for ages 12-17 years old, Closed for ages 6-11 years old
Principal Investigator: Rajiv Aggarwal, M.D.
CLIN-52120-464: A Phase III, Randomised, Double-Blind, Placebo-controlled, Multicentre, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic
Migraine in Adult Participants
Sponsor: Ipsen Innovation
Phase of Development: Phase III
Study Duration: Up to 60 weeks
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
